The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday broker round-up UPDATE

Wed, 22nd May 2013 09:37

Afferro Mining: Panmure Gordon reduces target price from 279p to 100p, while keeping its buy recommendation.Amara Mining: Westhouse Securities cuts target price from 110p to 90p retaining a buy recommendation.Amlin: Westhouse Securities moves target price from 455p to 470p and upgrades to add.ARM Holdings: Berenberg increases target price from 1150p to 1350p and maintains a buy recommendation.Beazley: Westhouse Securities shifts target price from 235p to 245p, while downgrading to neutral.Britvic: Investec places both its target price (prev.: 447p) and its buy recommendation under review.Burberry: JP Morgan increases target price from 1320p to 1400p and keeps a neutral rating. Deutsche Bank raises target price from 1400p to 1530p, while its hold recommendation remains unchanged. Credit Suisse ups target price from 1550p to 1600p and maintains an outperform rating.Capita Group: Investec ups target price from 865p to 1000p upgrading from sell to hold. HSBC Holdings increases target price from 775p to 1050p upgrading to neutral.Carnival: Morgan Stanley reduces target price from 2400p to 2200p, while reiterating an equal-weight rating. Deutsche Bank cuts target price from 2780p to 2640p staying with its buy recommendation. Exane takes target price from 2400p to 2200p and retains a neutral rating. HSBC Holdings reduces target price from 2900p to 2500p and downgrades to neutral.Catlin Group: Westhouse Securities takes target price from 530p to 590p upgrading to add.Darty: Citi shifts target price from 39p to 47p, but still recommends selling. Exane moves target price from 50p to 65p and maintains a neutral rating. Societe Generale takes target price from 51p to 68p, while downgrading to hold.Faroe Petroleum: Jefferies lowers target price from 210p to 200p, while keeping its buy recommendation.First Group: Morgan Stanley cuts target price from 195p to 176p, while upgrading to equal-weight.GlaxoSmithKline: Exane raises target price from 1400p to 1500p, but keeps its underperform rating.Great Portland Estates: Investec increases target price from 515p to 630p, while reiterating an add rating.Griffin Mining: Cantor Fitzgerald ups target price from 40p to 70p and upgrades to buy.Hikma Pharmaceuticals: Credit Suisse takes target price from 820p to 1050p, while its outperform rating is kept.Hiscox: Westhouse Securities shifts target price from 530p to 540p and keeps a neutral rating.Hogg Robinson Group: Investec lowers target price from 100p to 95p, while maintaining its buy recommendation. Canaccord Genuity shifts target price from 90p to 85p and retains a buy recommendation.Homeserve: Jefferies ups target price from 210p to 240p keeping a hold recommendation.HSBC Holdings: Bank of America ups target price from 755p to 785p and reiterates a neutral rating.Imagination Technologies Group: Berenberg reduces target price from 360p to 250p and leaves its sell recommendation unchanged.Informa: Westhouse Securities downgrades from add to neutral with a target price of 525p.Innovation Group: Investec moves target price from 30p to 33p maintaining a buy recommendation. Panmure Gordon shifts target price from 38p to 39p and keeps a buy recommendation.Invensys: Exane raises target price from 350p to 380p reiterating a neutral rating.Kazakhmys: UBS reduces target price from 465p to 385p and downgrades from buy to neutral.Magnolia Petroleum: Northland Capital initiates with a target price of 4.60p and a buy recommendation.Man Group: Citi moves target price from 110p to 130p and retains a neutral rating.Marks & Spencer: Nomura increases target price from 500p to 540p maintaining a buy recommendation. Citi ups target price from 440p to 470p and stays with its neutral rating. Deutsche Bank moves target price from 450p to 465p and leaves its hold recommendation unaltered. Exane raises target price from 310p to 390p keeping an underperform rating. Societe Generale ups target price from 472p to 581p and retains a buy recommendation. HSBC Holdings takes target price from 390p to 490p and maintains a neutral rating.MITIE: Jefferies cuts target price from 300p to 285p and maintains a hold recommendation.NetDimensions: Panmure Gordon ups target price from 118p to 124p reiterating its buy recommendation.Novae Group: Westhouse Securities raises target price from 450p to 500p and retains a neutral rating.Optimal Payments: Canaccord Genuity takes target price from 200p to 220p and retains a buy recommendation.Optos: N+1 Singer reduces target price from 150p to 135p, while upgrading to hold.Paragon Group: JP Morgan moves target price from 300p to 361p maintaining an overweight rating.Petropavlovsk: Westhouse Securities lowers target price from 285p to 275p keeping its buy recommendation.PZ Cussons: Panmure Gordon increases target price from 380p to 400p and retains a hold recommendation.RPS Group: Jefferies lowers target price from 285p to 275p, while leaving its buy recommendation unchanged.Shaftesbury: Investec takes target price from 550p to 690p and retains a hold recommendation.UK Mail Group: Investec raises target price from 465p to 600p and stays with its buy recommendation.Vectura: JP Morgan shifts target price from 133p to 148p and stays with its overweight rating.
More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.